Isoliquiritigenin / SOD Cancer Research Results

ISL is a distinct natural chalcone, chemically identified as 2′,4′,4-trihydroxychalcone, found particularly in licorice species such as Glycyrrhiza spp.ISL has substantial preclinical evidence involving anticancer, anti-inflammatory, antioxidant, metabolic, and neuroprotective effects. Reported anticancer actions include inhibition of proliferation, angiogenesis, EMT, invasion, and metastasis, with induction of apoptosis, cell-cycle arrest, autophagy, or ferroptosis depending on the model. Frequently reported pathways include PI3K/AKT/mTOR, NF-κB, STAT3, MAPK, Wnt/β-catenin, Nrf2, and Src signalling.

Isoliquiritigenin — isoliquiritigenin (ISL; 2′,4′,4-trihydroxychalcone) is a naturally occurring polyphenolic chalcone found particularly in licorice roots from Glycyrrhiza species. It is formally classified as a flavonoid-family chalcone rather than an isoflavone. ISL is a pleiotropic experimental bioactive compound with anticancer, anti-inflammatory, metabolic, antioxidant/pro-oxidant, and neuroprotective activities. Anticancer effects are strongly model- and concentration-dependent, and clinically relevant systemic exposure to unconjugated ISL is substantially more limited than the micromolar concentrations commonly used in cell culture. ISL also has weak phytoestrogenic activity and can interact with estrogen receptors.

Primary mechanisms (ranked):

1. Suppression of PI3K/AKT/mTOR survival and growth signalling, with associated apoptosis, autophagy, cell-cycle arrest, and inhibition of metabolic reprogramming.
2. Mitochondrial apoptosis through ↑ Bax/Bcl-2 ratio, mitochondrial dysfunction, cytochrome-c release, and caspase activation.
3. Suppression of JAK/STAT signalling, particularly JAK2/STAT3, reducing survival, proliferation, inflammatory signalling, and treatment resistance.
4. ROS-dependent cytotoxic signalling in several cancer models, including ROS-mediated inhibition of p38/mTOR/STAT3 and activation of mitochondrial apoptosis.
5. Suppression of NF-κB-mediated inflammatory and prosurvival signalling.
6. Inhibition of EMT, invasion, and metastasis through pathways including PI3K/AKT, β-catenin, MMPs, Snail-family transcription factors, and restoration of E-cadherin.
7. Suppression of tumor lipid synthesis and metabolic adaptation through AMPK activation with inhibition of SREBF1/FASN and, in colorectal cancer, FGFR4-associated lipid metabolism.
8. Modulation of arachidonic-acid/eicosanoid signalling, including inhibition of COX-2, mPGES-1, and CYP4A11 in selected tumor models.
9. NRF2 modulation is context-dependent: NRF2 activation can provide antioxidant and anti-inflammatory protection in non-malignant/neural models, whereas suppression of NRF2 antioxidant defence has been reported as a mechanism of radiosensitization in some cancer models.
10. Weak estrogen-receptor agonist/SERM-like activity; low concentrations may stimulate ER-responsive cells under some conditions, making this a relevant mechanistic and safety consideration rather than a uniformly anticancer effect.

Bioavailability / PK relevance: Oral ISL undergoes substantial intestinal absorption barriers and rapid phase-II metabolism, particularly glucuronidation. Animal studies report oral bioavailability of roughly 20–34%, but circulating parent ISL is transient and extensively converted to conjugated metabolites. Human pharmacokinetic studies of licorice-containing Kampo preparations confirm detectable ISL exposure but at levels substantially below many experimental cancer-cell concentrations. Low aqueous solubility and rapid metabolism have driven development of nanoparticles, micelles, SMEDDS, and structural derivatives to improve exposure.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100+ µM ISL, whereas parent-compound concentrations achieved after conventional oral botanical exposure are generally much lower because of rapid intestinal glucuronidation and systemic metabolism. Consequently, direct translation of high-micromolar in-vitro cytotoxicity to oral supplementation is poor. Some lower-concentration receptor, enzyme, inflammatory, and metabolic effects may be more pharmacologically plausible.

Clinical evidence status: Preclinical. Extensive cell-culture and multiple animal xenograft studies support anticancer activity, but ISL itself is not an established cancer treatment and there is no convincing randomized human anticancer efficacy evidence. Human studies primarily provide pharmacokinetic information from multi-component licorice/Kampo preparations rather than therapeutic evaluation of purified ISL. Drug-interaction potential involving CYP and UGT enzymes and weak estrogenic activity warrant caution.

Isoliquiritigenin Cancer-Relevant Mechanisms

Alzheimer’s disease relevance: ISL has meaningful but still preclinical AD relevance. In Aβ42-stimulated microglia, it activates NRF2 while suppressing NF-κB, inflammatory cytokines, nitric oxide, and oxidative injury, indirectly protecting neuronal cells. More recent mouse evidence reports improved cognition together with reduced tau phosphorylation, oxidative stress, mitochondrial dysfunction, neuronal loss, and synaptic impairment. Evidence remains limited to cellular and animal models; there is no established human AD therapeutic evidence.

Primary AD mechanisms (ranked):

1. Activation of NRF2 antioxidant defence with suppression of Aβ-associated oxidative stress.
2. Suppression of NF-κB-driven microglial neuroinflammation and inflammatory cytokine production.
3. Reduction of pathological tau phosphorylation in experimental AD models.
4. Protection of mitochondrial function and cellular ATP homeostasis.
5. Preservation of neuronal and synaptic markers with improvement of cognition in a mouse model.

Isoliquiritigenin Alzheimer’s-Relevant Mechanisms